PATHFAST Sepsis Marker

Sepsis with acute organ dysfunction (severe sepsis) is the number one cause of death in the non-coronary intensive care unit and one of the most significant challenges in critical care [1].


PATHFASTTM Presepsin is a chemiluminescent enzyme immunoassay (CLEIA) for the quantitative measurement of the Presepsin concentration in whole blood or plasma. PATHFASTTM Presepsin improves the diagnosis and prognosis of sepsis defining its level of severity. It is a valid indicator of risk stratification in septic patients. Due to the fast analysis in less than 17 minutes and the high prognostic value even at patient’s admission, PATHFASTTM Presepsin is useful in laboratories, emergency- and intensive care units and neonatal departments. An early diagnosis with an excellent prognostic performance and its ability to respond rapidly to the variety of clinical conditions make PATHFASTTM Presepsin the ideal tool for monitoring treatment, selecting the correct antibiotic-dose or changing it if ineffective.


The early recognition and diagnosis of sepsis is a crucial factor for improving patient outcomes. To address such challenges, a well-known and guideline-established biomarker for sepsis is useful. With its widely accepted usage and clinically proven usability, PCT becomes a viable option when it comes to answering the question “which biomarker can be used for diagnosis of septic patients?”
PCT is the 116 amino-acid precursor of the peptide hormone calcitonin. In healthy individuals, PCT is expressed by neuroendocrine C cells of the thyroid, pulmonary and pancreatic tissues. Upon formation, PCT is successively cleaved into calcitonin, katacalcin, and an N-terminal fragment [2]. Procalcitonin is expressed by different types of cells from numerous organs in response to pro-inflammatory stimulation, particularly systemic bacterial infection and sepsis [2-4]. PCT is used as an aid in the diagnosis of sepsis, severe sepsis and septic shock in systemic inflammatory response to bacterial infection, as well as in the assessment of the degree of sepsis severity [3]. PCT has shown to be useful in decision making to initiate, to monitor and to stop antibiotic treatment in randomized controlled clinical studies in patients with acute respiratory tract infections and sepsis [4-7].